China Insulin Industry Report, 2012-2015
  • Jan.2013
  • Hard Copy
  • USD $1,900
  • Pages:70
  • Single User License
    (PDF Unprintable)       
  • USD $1,800
  • Code: CYH007
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $2,800
  • Hard Copy + Single User License
  • USD $2,100
      

China is a country with the largest number of diabetics. In 2011, the market scale of diabetes medicine in China approximated RMB13.8 billion, of which, insulin medicines mainly comprising recombinant human insulin and insulin analog accounted for 52.8%.

Due to high technological content and entry barriers, Chinese insulin market is monopolized by foreign corporations. In 2011, the combined market share of the three world-renowned pharmaceutical tycoons including Novo Nordisk, Eli Lilly and Company, and Sanofi Group hit 90% in the Chinese market. By contrast, the largest domestic counterpart- Tonghua Dongbao Pharmaceutical -occupied merely 3.4% or so.

Denmark-based Novo Nordisk is not only the leader in global insulin industry, but also a major supplier in China’s insulin market with the recombinant human insulin market share of 76% and the insulin analog market share of 53% in 2011.

America-based Eli Lilly and Company is the second embarking on Chinese insulin market, with the recombinant human insulin market share of 17% and the insulin analog market share of 8% in 2011. Moreover, Eli Lilly and Company is making constant efforts to extend business in the Chinese market. In May, 2012, Eli Lilly and Company China R&D center was formally opened in Shanghai, dedicated to the R&D of diabetes medicines; in June, the Suzhou-based insulin extension project with the investment exceeding USD40 million was also put into service.

Jilin-based Tonghua Dongbao Pharmaceutical is China’s largest recombinant human insulin producer, with the insulin API capacity of 3,000 kg and the insulin preparation capacity of 70 million bottles or 6% market share in China’s recombinant human insulin market. In 2012, the company’s recombinant human insulin injection phase Ⅲ project with the annual capacity of insulin preparation targeting 126 million pcs started construction, and it is expected to be put into production in Q4 2013.

As the world’s fourth and China’s first insulin analog producer, Gan & Lee Pharmaceuticals realized the market share of 6% in China’s insulin analog market in 2011. In April 2012, the insulin phase Ⅲ project of the company held the groundbreaking ceremony. Once the project is put into production as scheduled, the company is expected to increase its capacity of insulin API by 750kg/a and of insulin preparation by 38.5 mln pcs/a.

Enterprises including Hisun Pharmaceutical, United Laboratories and Bayer, with positive outlook of demand for insulin in the Chinese market, are beefing up gaining ground in China through developing new products, building new production bases and agent marketing.

The report highlights the followings:

Global insulin industry: development, supply & demand, product R&D, competition pattern, development trend, etc.
China insulin industry: development, supply & demand, import & export, competition pattern, policy environment, development trend, etc.
Operation, insulin business analysis and development outlook of seven insulin producers worldwide.


1. Insulin Overview
1.1 Definition
1.2 Classification
1.3 Industry Chain

2. Global Insulin Market Development
2.1 Status Quo
2.2 Supply and Demand
2.3 Product R&D
2.4 Competition Pattern
2.5 Development Trend

3. China Insulin Market Development
3.1 Status Quo
3.2 Supply and Demand 
3.3 Export
3.4 Import
3.5 Competition Pattern
3.6 Price
3.7 Policy
3.8 Development Trend

4. Key Insulin Manufacturers
4.1 Novo Nordisk
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 R&D and Investment
4.1.6 Insulin Business
4.1.7 Business in China
4.1.8 Development Prospect
4.2 Eli Lilly and Company
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 R&D and Investment
4.2.6 Insulin Business
4.2.7 Business in China
4.2.8 Development Prospect
4.3 Sanofi Group
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 R&D and Investment
4.3.6 Insulin Business
4.3.7 Business in China
4.3.8 Development Prospect
4.4 Tonghua Dongbao Pharmaceutical Co., Ltd.
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 Customers
4.4.6 R & D and Investment
4.4.7 Insulin Business
4.4.8 Development Prospect
4.5 Wanbang Biopharmaceuticals 
4.5.1 Profile
4.5.2 Operation
4.6 Gan & Lee Pharmaceuticals
4.6.1 Profile
4.6.2 Operation
4.7 Nanjing Xinbai Pharmaceutical Co. Ltd.
4.7.1 Profile
4.7.2 Operation
4.7.3 Insulin Business

Diabetes Types
Classification of Insulin by Technological Level/Time
Recombiant Human Insulin Production Carrier and Featuers 
Insulin Industy Chain 
World’s Population of Diabetics, 2005-2012 
Population of Diabetics in the World’s Top 10 Countries by Diabetes Developers, 2011 
Market Size of the World’s Top 10 Diabetes Medicines, 2011
Market Scale of Diabetes Medicines Worldwide and YoY Growth Rate, 2004-2011 
Global Diabetics Market Occupancy by Medicine, 2006-2011
Global Insulin Market Scale and YoY Growth Rate, 2005-2011 
Theoretic Demand for Insulin API Worldwide, 2011
Average Per Capita Insulin Consumption Worldwide by Nation, 2000-2010 
R&D Advance of Some Insulin Products Worldwide as of late Jun. 2012 
Global Insulin Pump Market Scale, 2009/2016 
Global Insulin Market Share by Enterprise, 2011 
Global Insulin Production Line and R&D Input Share by Enterprise, 2011 
Population of Diabetics in China, 2007-2011
Market Scale of Diabetes Medicines in China and YoY Growth Rate, 2004-2011
Insulin Medicine Market Share in China, 2006-2011
Market Share of Diabetes Treatment Hospitals in China by Medicine, 2005-2010 
Export Value and Export Price of Insulin and Insulin Salts of China, 2008-2012 
Export Destinations of Insulin and Insulin Salts in China and Proportions, 2011 
Export Value of Insulin-Containing Medicines with Unmeasued Dose in China,2010-2012 
Export Value of Insulin-Containing Medicines with Measued Dose in China by Nation and Proportions, 2011
Export Value of Insulin-Containing Medicines with Measued Dose in China and YoY Growth Rate, 2008-2012
Export Value of Insulin-Containing Medicines with Measued Dose in China by Nation, 2011 
Import Value of Insulin and Insulin Salts and YoY Growth Rate in China, 2008-2011 
Import Value of Insulin and Insulin Salts in China by Country, 2011 
Import Value of Insulin-Containing Medicines with Measued Dose and YoY Growth Rate in China, 2008-2012 
Import Value of Insulin-Containing Medicines with Measued Dose in China by Country, 2011 
Import Value of Insulin Medicines in Representative Hospticals in 22 Cities across China by Variety, 2008-2011
Competitive Enterprises and Market Share in China Insulin Market, 2011 
Competition Pattern of China Recombinant Human Insulin Market, 2011
Competition Pattern of China Insulin Analog Market by Enterprise, 2011 
Ceiling Retail Price of Some Insulin Products in China, 2011 
Insulin Medicines Included in National Health Insurance Directory, 2012 
Key Strategy of Novo Nordisk
Revenue and YoY Growth Rate of Novo Nordisk, 2007-2012
Net Income and YoY Growth Rate of Novo Nordisk, 2007-2012
Revenue of Novo Nordisk by Product, 2007-2012
Revenue of Novo Nordisk by Region, 2007-2012 
Gross Margin of Novo Nordisk, 2007-2012 
R&D Expenditure of Novo Nordisk by Field, 2007-2011
Insulin Market Share of Novo Nordisk by Country, 2011-2012 
Revenue from Insulin Business of Novo Nordisk by Mark, 2009-2012 
Distribution of Subsidaries under Novo Nordisk in China
Revenue and YoY Growth Rate of Novo Nordisk in China, 2007-2012 
Revenue, Net Income and YoY Growth Rate of Novo Nordisk, 2010-2015
Revenue and YoY Growth Rate of Eli Lilly and Company, 2007-2012 
Net Income and YoY Growth Rate of Eli Lilly and Company, 2007-2012 
Revenue of Eli Lilly and Company by Field, 2009-2011
Revenue of Eli Lilly and Company by Region, 2009-2011 
Consolidated Gross Margin of Eli Lilly and Company, 2008-2012 
R&D Expenditure and YoY Growth Rate of Eli Lilly and Company, 2007-2012 
Cooperative Enterperises with Eli Lilly and Company by Product, 2011 
Revenue and YoY Growth Rate from Insulin Business of Eli Lilly and Company by Product, 2008-2012
Revenue from Insulin Business of Eli Lilly and Company by Region, 2008-2012 
Revenue, Net Income and YoY Growth Rate of Eli Lilly and Company, 2010-2015 
Revenue and YoY Growth Rate of Sanofi Group, 2007-2012 
Net Income and YoY Growth Rate of Sanofi Group, 2007-2012 
Revenue of Sanofi Group by Business, 2008-2012
Revenue of Sanofi Group by Region, 2008-2012
Consolidated Gross Margin of Sanofi Group, 2007-2012 
R&D Expenditure of Sanofi Group by Business, 2008-2012 
Revenue and YoY Growth Rate from Insulin Business of Sanofi Group by Product, 2008-2012
Distribution of Subsidaries under Sanofi Group, 2011
Revenue and YoY Growth Rate of Sanofi Group in China, 2009-2012 
Revenue, Net Income and YoY Growth Rate of Sanofi Group, 2010-2015 
Distribution of Subsidaries under Tonghua Dongbao Pharmaceutical, 2011 
Revenue and YoY Growth Rate of Tonghua Dongbao Pharmaceutical, 2007-2012
Net Income and YoY Growth Rate of Tonghua Dongbao Pharmaceutical, 2007-2012 
Revenue of Tonghua Dongbao Pharmaceutical by Product, 2007-2012
Revenue of Tonghua Dongbao Pharmaceutical by Region, 2007-2012 
Gross Margin of Tonghua Dongbao Pharmaceutical by Product, 2007-2012 
Tonghua Dongbao Pharmaceutical’s Revenue from Top 5 Clients and % of Total Revenue, 2009-2012 
Namelist and Revenue Contribution of Tonghua Dongbao Pharmaceutical’s Top 5 Clients, 2011-2012 
Revenue and YoY Growth Rate from Insulin Business of Tonghua Dongbao Pharmaceutical, 2007-2012 
Revenue, Net Income and YoY Growht Rate of Tonghua Dongbao Pharmaceutical, 2010-2015 
Holding Subsidiaries of Wanbang Biopharmaceuticals
Total Assets and Net Income of Wanbang Biopharmaceuticals, 2009-2011
Insulin Products of Gan & Lee Pharmaceuticals
Revenue and Net Income of Gan & Lee Pharmaceuticals, 2008-2010 
Revenue, Net Income and YoY Growth Rate of Nanjing Xinbai Pharmaceutical, 2007-2011 
Revenue from Insulin Business of Nanjing Xinbai Pharmaceutical, 2008-2011
Gross Profit and Gross Margin from Insulin Business of Nanjing Xinbai Pharmaceutical, 2008-2011

China Diagnostic Reagent Industry Report, 2012-2014

China’s diagnostic reagent industry has formed a certain market scale and basis, and is marching from the introduction stage to the growth stage. With the continuous growth in China’s medical care inv...

Global and China Monoclonal Antibody Industry Report, 2013

In recent years, the monoclonal antibody market around the globe has witnessed substantial growth, and the CAGR of market scale during 1997-2011 has reached 44% approximately. It is predicted that the...

China Insulin Industry Report, 2012-2015

China is a country with the largest number of diabetics. In 2011, the market scale of diabetes medicine in China approximated RMB13.8 billion, of which, insulin medicines mainly comprising recombinant...

China Heparin Industry Report, 2012-2014

China, abundant in heparin raw materials, has become one of the world’s largest heparin API producers and exporters, owning to the quality of heparin API having won international recognition gradually...

China Blood Products Industry Report, 2011-2012

Blood plasma serves as key raw material in blood product industry. In August 2011, the shut-down of 16 plasma collection stations in Guizhou province, China resulted in a YoY decline of 15% in plasma ...

Company Study of Chongqing Zhifei Biological Products Co., Ltd, 2012

Chongqing Zhifei Biological Products Co., Ltd (Website:www.zhifeishengwu.com; Code:300122.SZ), hereinafter referred to as Zhifei Biological, was established in 1995 with the registered capital of RMB ...

Company Study of Walvax Biotechnology Co, Ltd.,2012

Walvax Biotechnology Co, Ltd. (Walvax Biotechnology for short), founded in 2001, specializes in research & development, production and marketing of bio-pharmaceutical vaccines. In September 2010, it w...

Company Study of Hualan Biological Engineering Ltd., 2011 (002007.SZ)

Hualan Biological Engineering Ltd., (hereinafter referred to as Hualan Biological) established in 1992, is a national key high-tech enterprise engaged in the R&D and production of blood products. ...

China Heparin Industry Report, 2010-2011

With richness in heparin materials and the quality of heparin API getting accredited by the international community, China has become one of the largest heparin API producers and exporters in the worl...

China Blood Products Industry Report, 2010-2011

Recent years have seen fast-growing development of blood product industry in China, with the enterprises concerned numbering 33 which can produce 10-odd blood products including human albumin, human i...

China Monoclonal Antibody Industry Report, 2010-2011

China has been engaging in the R&D of monoclonal antibody industry for a long time, but still lags far behind the European and American countries in terms of industrialization. In 2010, the market...

China Insulin Industry Report, 2010

In 2009, China’s insulin market size reached up to RMB5.3 billion, but still accounted for less than 6% of the global market. China has the world’s most diabetes patients, which is 92 million at prese...

China Heparin Industry Report, 2010

Although it is with rich source of heparin raw materials, China lags behind in the manufacturing technologies for heparin drugs. Chinese heparin industry presents mainly the exportation of heparin API...

China Blood Products Industry Report, 2010

In 2009, Chinese blood products market valued nearly RMB7 billion and it will continue to expand in the next two or three years. The main reasons include: The demand from the downstream of China bl...

Global and China Biopharmaceutical Industry Report, 2010

In recent years, biopharmaceutical industry has been the fastest growing sector in the global pharmaceutical industry. From 1998 to 2009, the compound annual growth rate of biopharmaceutical industry ...

China Blood Products Industry Report, 2009

The blood products industry has a strong ability to withstand risks and immunity to global financial crisis since it is not greatly influenced by periodicity. Owing to large demand gap, strict su...

China Listed Bio-pharmaceutical Companies Report, 2008

This report firstly gives an overview of China bio-pharmaceutical industry, and then analyses sub-industries, import & exports status of the industry; finally it expounds the operations and revenu...

China Blood Products Industry Report, 2007-2008

China blood products industry is all along comparatively independent from global blood products industry. In the year of 1986, according to the rules from Ministry of Health, China prohibited the impo...

China Biopharmaceutical Industry Report, 2007-2008

Pharmaceutical industry is a sunrise industry, especially the biopharmaceuticals, which just starts its large-scale industrialization process. Many large biotech and pharmaceutical companies are stren...

2005-2011 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1
在线客服系统